🇺🇸 FDA

Company profile · Sponsor

Y-Mabs

Y-Mabs Therapeutics A/S

E05B799 · EMA pharma EU
Pipeline
1
Drugs
0
Patents
0

Quick answer

Y-Mabs (E05B799) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E05B799
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (1)

Search pipeline →

  1. Humanized IgG1 monoclonal antibody against GD2, Leukine

    Y-Mabs

    Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Y-Mabs?

Y-Mabs (E05B799) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

What pipeline programs does Y-Mabs sponsor?

We track 1 ClinicalTrials.gov-linked program for Y-Mabs, including Humanized IgG1 monoclonal antibody against GD2, Leukine. Open each program for phase, modality, NCT IDs, and indication details.

Where does Y-Mabs company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.